| Reconociendo y manejando una crisis de hipertermia maligna: Guías del Grupo Europeo de Hipertermia Maligna |
Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group K. P. E. Glahn1,F. R. Ellis, P. J. Halsall, C. R. Müller, M. M. J. Snoeck, A. Urwyler and F. Wappler Danish Malignant Hyperthermia Centre, Department of Anaesthesia, University Hospital Herlev, Copenhagen, Denmark. University of Leeds, Leeds, UK. MH Investigation Unit, St James University Hospital, Leeds, UK . Department of Human Genetics, University of Würzburg, Germany. MH Investigation Unit, Nijmegen, The Netherlands. Department of Anaesthesia and Research, University of Basel, Switzerland. Department of Anaesthesiology and Intensive Care Medicine, Hospital Cologne-Merheim, University Witten-Herdecke, Cologne, Germany British Journal of Anaesthesia 105 (4): 417-20 (2010) Abstract Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large areas around the world thereby increasing the risk of MH fatalities in these areas. The European Malignant Hyperthermia Group collected and reviewed all guidelines available from the various MH centres in order to provide a consensus document. The guidelines consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH crisis. Lea este artículo completo en PDF en el siguiente link: |
| Tendencias y resultados de la hipertermia maligna en Estados Unidos, 2000 a 2005. |
Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Department of Surgery, Division of Vascular Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9157, USA.eric.rosero@utsouthwestern.edu Anesthesiology. 2009 Jan;110(1):89-94 Abstract BACKGROUND: Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic disorder with an estimated mortality of less than 5%. The purpose of this study was to evaluate the current incidence of MH and the predictors associated with in-hospital mortality in the United States. METHODS: The Nationwide Inpatient Sample, which is the largest all-payer inpatient database in the United States, was used to identify patients discharged with a diagnosis of MH during the years 2000-2005. The weighted exact Cochrane-Armitage test and multivariate logistic regression analyses were used to assess trends in the incidence and risk-adjusted mortality from MH, taking into account the complex survey design. RESULTS: From 2000 to 2005, the number of cases of MH increased from 372 to 521 per year. The occurrence of MH increased from 10.2 to 13.3 patients per million hospital discharges (P = 0.001). Mortality rates from MH ranged from 6.5% in 2005 to 16.9% in 2001 (P < 0.0001). The median age of patients with MH was 39 (interquartile range, 23-54 yr). Only 17.8% of the patients were children, who had lower mortality than adults (0.7% vs. 14.1%, P < 0.0001). Logistic regression analyses revealed that risk-adjusted in-hospital mortality was associated with increasing age, female sex, comorbidity burden, source of admission to hospital, and geographic region of the United States. CONCLUSIONS: The incidence of MH in the United States has increased in recent years. The in-hospital mortality from MH remains elevated and higher than previously reported. The results of this study should enable the identification of areas requiring increased focus in MH-related education. |
No hay comentarios:
Publicar un comentario